Method of attenuating reactions to skin irritants
CA 2441893 C · Owner: Dana-Farber Cancer Institute, Inc. · Inventors: Gillessen, Silke; Wilson, S. Brian; Dranoff, Glenn
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1drestricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g. contact hypersensitivity) for systemic , administration to attenuate ongoing immune responses and to provide , hypoallergenic cosmetic products including pharmaceutical cosmetic, and skin , care compositions. Preferably these compositions are in a form intended for topical administration.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 2002 and granted January 20, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 26, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.